NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCATS E-257-2010-0-JP-07 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators JP National Stage 2013-543335 Issued
NCATS E-257-2010-0-CN-10 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators CN National Stage 201180066859.7 Issued
NCATS E-257-2010-0-RU-14 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators RU National Stage 2013126094 Issued
NCATS E-257-2010-0-AU-03 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators AU National Stage 2011338377 Issued
NIDCR E-300-2008-0-US-03 Identification Of DSG-3 As A Biomarker For The Detection Of Metastasis In Lymph Nodes US National Stage 13/376,984 9151762 Issued PDF
NCATS E-257-2010-0-ZA-15 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators ZA National Stage 2013/04215 Issued
NCATS E-257-2010-0-PCT-02 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators PCT PCT PCT/US2011/063928 Expired
NHGRI E-044-2013-0-US-01 Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human Lamin A (LMNA) US 61/568,590 Abandoned
NIAID E-051-2012-0-US-01 Neutralizing Antibodies To HIV-1 And Their Use US 61/568,520 Abandoned
NCI E-294-2010-0-PCT-02 PHARMACEUTICAL COMPOSITION COMPRISING NANOG SHRNA, AND METHOD OF USNIG NANOG SHRNA TO TREAT CANCER PCT PCT PCT/US2011/063451 Expired
NCI E-069-2010-0-PCT-02 MODULATING IMMUNE CELL ACTIVITY USING CYTOKINE-INDUCED SRC HOMOLOGY 2 AND/OR HIGH TEMPERATURE REQUIREMENT A-1 PCT PCT PCT/US2011/63375 Abandoned
E-237-2014-0-US-01 Cerium Oxide Nanoparticles And Associated Methods For Promoting Wound Healing US 61/567,184 Abandoned
NIAID E-041-2012-0-US-01 Development Of Anti-Idiotypic Antibodies Against HIV Neutralizing Monoclonal Antibodies US 61/567,482 Abandoned
NINDS E-133-2006-1-US-12 Compounds For The Treatment Of Spinal Muscular Atrophy And Other Uses US DIV 13/310,965 Abandoned
NINDS E-043-2012-0-US-01 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging US 61/630,101 Abandoned
NIA E-045-2012-0-US-01 THIO COMPOUNDS US ORD 13/310,242 8927725 Issued PDF
NIAID E-051-2002-0-US-07 METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION US DIV 13/310,264 8716301 Expired PDF
NIAID E-123-2007-0-US-05 Monoclonal Antibodies That Neutralize Anthrax Toxin US DIV 13/310,463 8574853 Abandoned PDF
NIAID E-575-2013-0-US-01 VACCINE FOR FALCIPARUM MALARIA US 61/566,365 Abandoned
NIAID E-031-2012-0-US-01 Chimeric JEV/DEN4 Vaccine Candidates For Control Of Japanese Encephalitis US 61/566,560 Abandoned
NIAID E-268-2010-0-PCT-02 Treatment of Inflammatory Diseases by Targeting the Adaptor Protein CIKS PCT PCT PCT/US2011/062945 Expired
NCI E-058-2015-0-US-01 THE MECHANISM OF NSAID CHEMOPREVENTION IN COLORECTAL CANCER US 61/565,540 Abandoned
NCI E-039-2011-0-EP-05 Chimeric Rabbit/Human ROR1 Antibodies EP National Stage 11791733.6 Issued
NCI E-039-2011-0-AU-03 Chimeric Rabbit/Human ROR1 Antibodies AU National Stage 2011336650 Issued
NIAAA E-061-2010-0-CN-07 PROCESS FOR THE PREPARATION OF (3R).HYDROXYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE CN National Stage 200980159591.4 Abandoned
NCI E-039-2011-0-PCT-02 Chimeric Rabbit/Human ROR1 Antibodies PCT PCT PCT/US2011/062670 Expired
NCI E-018-1999-1-US-03 Molecular Motor US DIV 13/306,774 8798980 Abandoned PDF
NCI E-178-2009-0-US-03 Anti-Tnf Induced Apoptosis (ATIA) Diagnostic Markers And Therapies US National Stage 13/322,863 9989533 Abandoned PDF
NIAID E-089-2002-1-US-45 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US DIV 13/305,639 9783787 Expired PDF
NCI E-304-2006-0-US-04 Modified T Cell Receptors and Related Materials and Methods US DIV 13/304,841 9128080 Issued PDF
NHLBI E-082-2001-0-US-04 Real-Time, Interactive Volumetric Magnetic Resonance Imaging US CON 13/305,496 9008751 Expired PDF
NCI E-195-2001-0-JP-18 Phytoestrogenic Isoflavone Compositions, Their Preparation, And Use Thereof For Protection Against Treatment of Radiation Injury JP DIV 2011-256095 Expired
NIAID E-078-2009-0-US-04 Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses US National Stage 13/322,317 8568739 Abandoned PDF
NCI E-173-2012-0-US-01 USE OF PDL1 EXPRESSING CELLS TO CONVERT T CELLS INTO REGULATORY T CELLS US 61/563,273 Abandoned
NCI E-173-2012-1-US-01 Programmed Death Ligand-1 (PDL1)-transduced K562 Cells Convert Human Th1 Cells Into Regulatory T Cells US 61/564,174 Abandoned
NCI E-196-2000-0-US-06 Defensin-Antigen Fusion Proteins US DIV 13/303,081 8551936 Abandoned PDF
NCI E-119-2011-0-PCT-01 Gene Expression Signature For The Prognosis of Epithelial Cancer PCT PCT PCT/US2011/061871 Expired
NIA E-019-2011-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA PCT PCT PCT/US2011/061872 Abandoned
NCATS E-277-2011-0-US-01 Modulators Of Lipid Storage US 61/562,894 Abandoned
NCI E-255-2011-0-US-01 A Method for Positively or Negatively Regulating the Assembly of Newly Synthesized CENP-A to Exogenous Alphoid DNA Containing CENP-B Boxes in Mammalian Cell Lines US 61/562,825 Abandoned
NINDS E-206-2011-2-US-01 USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TRZAT GAUCHER'S DISEASE US 61/561,747 Abandoned
NCI E-254-2005-2-NZ-14 Codon Optimized IL-15 and IL-15R-Alpha Genes for Expression in Mammalian Cells NZ DIV 596494 Issued
NCI E-038-2012-0-US-01 Development Of Therapeutic RNA Switches To Eradicate Viral Reservoirs In HIV-Infected Patients US 61/561,247 Abandoned
NCI E-039-2012-0-US-01 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP): A Novel Concept For HIV Treatment US 61/561,257 Abandoned
NCI E-184-2009-0-KR-07 COMBINATION IMMUNOTHERAPY COMPOSITIONS AGAINST CANCER AND METHODS KR National Stage 10-2011-7027319 Issued
NCI E-076-2013-0-US-02 Bispecific EGFRvIII Antibody Engaging Molecules US ORD 13/296,809 9249217 Issued PDF
NCI E-181-2009-2-US-02 Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain and Methods of Use US National Stage 13/320,726 9175038 Abandoned PDF
NCI E-290-2006-2-US-13 METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-10a US DIV 13/296,500 8343725 Abandoned PDF
NCI E-290-2006-2-US-10 METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-29a US DIV 13/296,448 8338106 Abandoned PDF
NCI E-290-2006-2-US-09 METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-203 US DIV 13/296,371 8338105 Abandoned PDF